Sobi announces topline phase 3 data of avatrombopag for the treatment of Chemotherapy-Induced Thrombocytopenia
- Friday, October 9, 2020, 7:13
- PR Newswire
- Add a comment
STOCKHOLM, Oct. 9, 2020 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced topline results from its phase 3 study of avatrombopag, an oral thrombopoietin (TPO) receptor agonist, in solid tumour cancer patients with chemotherapy-induced thrombocytopenia…
About the Author
admin has written 21081 stories on this site.